The treatment of chronic hepatitis B has improved substantially in recent years. FDA-approved therapies now include interferon α, pegylated interferon α2a, lamivudine, adefovir dipivoxil, and entecavir. Other antiviral agents and combination regimens are in various stages of development. This Review summarizes the results obtained for approved therapies and highlights emerging antiviral agents for the treatment of chronic hepatitis B.
- Smruti R Mohanty
- Sonia S Kupfer
- Vijay Khiani